
FDA Approves Teal Health’s Teal Wand™—The First and Only At-Home Self-Collection Device for Cervical Cancer Screening
On May 9, 2025, Teal Health® announced the Food and Drug Administration’s (FDA) approval of the Teal Wand™, the first and only at-home vaginal sample self-collection device for cervical cancer screening in the United States.
Cervical cancer screenings, commonly referred to as the Pap smear, are critical to a woman’s health, but they are inconvenient and uncomfortable for most. Now women have a new way to screen that is as accurate as going to the doctor’s office, comfortable, and done from home.
The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged 25–65 at average risk. The at-home screening includes both the Teal Wand collection kit and an end-to-end telehealth service providing virtual access to Teal medical providers who prescribe the kit, review the results from the lab, and support women throughout their at-home screening experience.
Cervical cancer is one of the only cancers that is almost entirely preventable with regular screening, yet more than 1 in 4 women in the U.S. are behind. Whether it’s because a woman can’t get time off work, is unable to find an available appointment, or avoids the discomfort of an in-clinic exam, Teal can provide a comfortable and convenient option.
The Teal Wand is a preferred alternative, one that has been built with empathy, is driven by science, and designed to make screening easy, so that more women can take control of their health on their own terms.
Teal Health’s FDA approval was supported by their SELF-CERV study, the largest U.S.-based comparative study of its kind. The study confirmed that self-collected samples using the Teal Wand have the same performance as clinician-collected samples, proven to detect cervical precancer 96% of the time, and that the Teal Wand is a much preferred experience.
Notably, 86% of participants said they’d be more likely to stay up to date with cervical cancer screening if they could do it at home, and 94% said they would prefer to self-collect at home with the Teal Wand if they knew it was accurate. The clinical performance and preference for the Teal Wand, alongside Teal’s comprehensive telehealth service, highlight the potential of at-home self-collection to expand access to high-quality cervical cancer screening and improve outcomes.
Tags:
Source: U.S. Food and Drug Administration
Credit:
